Synthesis and biological activity of a-glucosyl C24:0 and C20:2 ceramides was the stereoselective synthesis of the a-glycosidic linkage. Of the methods examined, glycosylation using per-TMS-protected glucosyl iodide 16 was completely a-selective and provided gram quantities of amine 11, from which a-glucosyl ceramides 4 and 5 were obtained by N-acylation. a-GlcCer 4, containing a C24 saturated acyl chain, stimulated a marked proliferation and expansion of human circulating iNKT cells in short-term cultures. a-GlcCer 5, which contains a C20 11,14-cis-diene acyl chain (C20:2), induced extremely similar levels of iNKT cell activation and expansion. Ó 2010 Elsevier Ltd. All rights reserved.
CD1d is a non-polymorphic glycoprotein expressed on the surface of antigen-presenting cells (APCs). It is specifically associated with presenting lipid antigens that activate the distinctive class of T cells known as invariant Natural Killer T (iNKT) cells. iNKT cells display characteristics of both T cells and NK cells and play a crucial role in diverse immune responses and other pathologic conditions. [1] [2] [3] [4] When the synthetic glycolipid a-galactosyl ceramide (a-GalCer), 5 also known as KRN7000 (1, Fig. 1 ), is bound to CD1d and presented to T cell receptors (TCRs) on the surface of iNKT cells, the latter are activated to release diverse cytokines, including both Th1 and Th2 cytokines. [6] [7] [8] Similar results are obtained with the more readily obtained C24:0 analogue (2, Fig. 1 ). 9, 10 It is believed that the release of Th1 cytokines may contribute to antitumour and antimicrobial functions, whilst the secretion of Th2 cytokines may help alleviate autoimmune diseases [11] [12] [13] such as multiple sclerosis 14 and arthritis. 15 The opposing effects induced by Th1 and Th2 cytokines have complicated efforts to develop KRN7000 as a therapeutic agent, since it induces high levels of both types of cytokine and therefore may induce mixed and unpredictable biological effects. 16 Switching the C26:0 acyl chain of KRN7000 for a C20 11,14-cis-diene acyl chain modifies the outcome of iNKT cell activation and potently induces a Th2-biased cytokine response. 9 This C20:2 analogue (3, Fig. 1 ) also exhibits less stringent requirements for loading on to CD1d. 10 Although extensive studies have examined the impact on the iNKT cell-stimulating activities of modifications to the fatty acyl and sphingosine structures of a-GalCer, there has been less analysis of the effects of structural modifications of the carbohydrate head group. 17 Subtle changes in this part of the glycolipid are likely to have significant effects on iNKT cell recognition since the monosaccharide group is exposed and makes direct contacts with the TCR in complexes formed by the binding of a-GalCer to CD1d. 18 To this end, we now report the synthesis and preliminary biological activity of a-glucosyl ceramide analogues 4 and 5 (Fig. 2) . Since targets 4 and 5 differ only in their acyl chain substitution, we elected to pursue a synthetic strategy that would allow the introduction of this point of diversity in the final step. We therefore examined several routes to amine 11 from which both glucosyl ceramide targets would then be accessed through chemoselective acylation of the amino residue. The key challenge in a synthesis of amine 11 is to form the glycosidic linkage with high a-selectivity. To this end, we first opted to employ a stereospecific glucosylation method developed by Bols (Scheme 1). 19 This method involves the use of a silyl tether to attach the acceptor temporarily to the 2-position of the glucosyl donor prior to the key glycosylation step. form mixed silyl acetal 9, our glucosylation precursor, in modest yield. Treatment of silyl acetal 9 with N-iodosuccinimide (NIS) furnished the desired glucoside 10 as a single diastereoisomer, albeit in modest yield. Hydrogenolysis of the benzyl groups and reduction of the azide in 10 using Pd(OH) 2 as the catalyst, 22 provided our acylation precursor, amine 11 in 57% yield (Scheme 1). Although this synthetic approach allowed a completely stereoselective route to our target amine 11, a number of steps in the sequence suffered from poor yields, which hindered access to significant quantities of material. We therefore examined other glycosylation methods. Kobayashi has described a stereoselective a-glycosylation using a galactosyl bromide generated in situ from 2,3,4,6-tetra-O-benzyl galactose. 23 Unfortunately, we found that glycosylation using the corresponding glucosyl bromide derived from 12 afforded significant amounts of the unwanted b-anomer (Scheme 2). The use of perbenzylated glucosyl fluoride 13 24 also provided a mixture of a-and b-glycosides 14, which proved difficult to separate (Scheme 2). We therefore turned our attention to the use of glucosyl iodides, 25 acylation reactions were accomplished by adding either tetracosanoyl chloride or 11,14-eicosadienoyl chloride (formed from the corresponding carboxylic acids using oxalyl chloride) in THF to amine 11 in a vigorously stirred biphasic mixture of THF and 8 M NaOAc solution. Both reactions provided the desired amide products 4 and 5 in good yields (Scheme 3). 30, 31 To assess the biological activity of the a-glucosyl ceramides 4 and 5 and compare these to KRN7000 1 and the a-galactosyl ceramide analogues 2 (C24:0) and 3 (C20:2), we assessed the ability of each compound to induce the expansion of iNKT cells in samples of human peripheral blood mononuclear cells (PBMC) during an eight-day in vitro culture. 32 The results showed that both the percentages and absolute numbers of iNKT cells in the cultures were markedly increased to similar levels by stimulation with both of the a-GlcCer analogues 4 and 5 ( Fig. 3) . The level of iNKT cell expansion, at least with a relatively high concentration of the glycolipids (250 nM), was comparable for both of the N-acyl variants of a-GlcCer and very similar to levels obtained with the related a-GalCer analogues (2 (C24:0) and 3 (C20:2)) and with the prototypical iNKT cell activator KRN7000 (1 (C26:0)). Representative profiles obtained by flow cytometry of cultures from one normal blood donor are shown in Figure 3A . This analysis was carried out with PBMC from four separate donors (Fig. 3B) . Although differences were observed for the levels of iNKT cell expansion between different donors, all donors responded well to the two a-GlcCer analogues. In all cases, these responses were similar to those generated by the analogous a-GalCer compounds.
The strong biological activity of the a-GlcCer compounds was consistent with findings from the initial study that described the reactivity of CD1d-restricted iNKT cells to synthetic glycosylceramides. 5 This showed an a-GlcCer with a C26 saturated acyl group to be stimulatory for mouse iNKT cells, with a level of activity only slightly less than that of KRN7000 (1) . Our analysis confirms the activity of a-GlcCer compounds as ligands for human iNKT cells.
It is also notable that we observed human iNKT cell activation and expansion for an a-GlcCer with a shorter acyl chain containing unsaturations (5) . Previous work with analogues of a-GalCer containing C20:2 or other unsaturated fatty acyl groups revealed a marked tendency for these to bias iNKT cell-dependent cytokine responses in mice to give preferential secretion of Th2 cytokines such as IL-4 and IL-13. 9 This Th2 cytokine bias has been associated with therapeutic benefits in a variety of mouse models of autoimmune and inflammatory diseases, indicating potential therapeutic applications for such glycolipids in human diseases. 17 It will thus be important to determine whether compound 5 or other a-GlcCer analogues bearing an unsaturated acyl chain also show an ability to induce Th2-biased cytokine responses, which is a focus for future studies.
In summary, we have developed an efficient route to a-glucosyl ceramides that provided two biologically active ligands 4 and 5 for stimulation of human iNKT cell responses. Of the range of glycosylation methods that were investigated for accessing the target molecules with high levels of stereoselectivity, the use of per-TMS-protected glucosyl iodide 16 as the donor is the most attractive, reacting with acceptor 17 to provide a single a-glycoside product. This glycosylation reaction is also scalable and with an acidic work-up effecting global deprotection, followed by Staudinger reduction of the azide, allows rapid access to advanced intermediate 11, which can now be used to provide a broad range of a-GlcCer compounds with different acyl chains. Compounds produced using this approach will assist in expanding the current understanding of the structure-activity relationships for glycolipid activators of iNKT cells, which is of central importance to the further development of this class of compounds as clinically useful immunomodulators. foetal calf serum and recombinant IL-2 (60 IU/mL) and IL-7 (5 ng/mL) (Peprotech). Glycolipids were solubilised in 100% DMSO and added directly to culture media to achieve a final concentration of 250 nM. Control wells received an amount of DMSO vehicle identical to that added with the glycolipids (0.00125%). Cultures were incubated for 8 days at 37°C in a 5% CO 2 humidified incubator. Cultures were harvested and the cells stained with fluorochrome labelled monoclonal antibodies specific for CD3 and the iNKT cell TCR (6B11, eBiosciences). Samples were also stained with propidium iodide to exclude dead cells, and a known number of Caltag fluorescent counting beads (Invitrogen) were added to the samples to allow quantitation of absolute cell numbers. The total number of iNKT cells (CD3 + , 6B11 + , PI negative lymphocytes) was calculated by normalising according to counting beads and the fold expansion values were calculated based on the initial number of iNKT cells. Data were collected on a FACSCalibur flow cytometer using CellQuest software (BD Biosciences).
